Therapeutic implications of biomarkers in chronic heart failure

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 468-479

  Ahmad, T ^a   O'Connor, C M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUCOSAMINIDASE; ADRENOMEDULLIN; ALDOSTERONE; BIOLOGICAL MARKER; COPEPTIN; CYSTATIN C; ENDOTHELIN 1; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; KIDNEY INJURY MOLECULE 1; MATRIX METALLOPROTEINASE; NEU DIFFERENTIATION FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NORADRENALIN; RENIN; TROPONIN;

ACUTE CORONARY SYNDROME; APOPTOSIS; ARTICLE; CLINICAL TRIAL (TOPIC); DIURETIC THERAPY; ERYTHROCYTE; FIBROSING ALVEOLITIS; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HORMONE ACTION; HUMAN; INFLAMMATION; KIDNEY FAILURE; LIVER CIRRHOSIS; MEMBRANE PERMEABILITY; MUSCLE MASS; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA OSMOLARITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THORAX RADIOGRAPHY;

BIOMARKERS, PHARMACOLOGICAL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MODELS, CARDIOVASCULAR; NATRIURETIC PEPTIDES;

EID: 84884498241     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.139     Document Type: Article

References (75)

1. Katz, A.M. The "modern" view of heart failure: how did we get here? Circ. Heart Fail. 1, 63-71 (2008).
2. Braunwald, E. Heart failure. JACC 1, 1-20 (2013).
3. Motiwala, S.R. & Januzzi, J.L. Jr. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin. Pharmacol. Ther. 93, 57-67 (2013).
4. Yancy, C.W. et al.; ACCF/AHA Task Force Members. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. S0735-1097, 02114-1 (2013).
5. Ahmad, T., Fiuzat, M., Felker, G.M. & O'Connor, C. Novel biomarkers in chronic heart failure. Nat. Rev. Cardiol. 9, 347-359 (2012).
6. Loscalzo, J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation 125, 638-645 (2012).
7. Stevenson, L.W. & Perlof, J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261, 884-888 (1989). (Pubitemid 19046417)
8. van Kimmenade, R.R. & Januzzi, J.L. Jr. Emerging biomarkers in heart failure. Clin. Chem. 58, 127-138 (2012).
9. Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med. 358, 2148-2159 (2008).
10. Cohn, J.N. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819-823 (1984). (Pubitemid 14035089)
11. Cohn, J.N. & Tognoni, G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001). (Pubitemid 33126822)
12. Latini, R. et al.; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J. 25, 292-299 (2004). (Pubitemid 38295437)
13. Teerlink, J.R. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr. Heart Fail. Rep. 2, 191-197 (2005).
14. Schrier, R.W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med. 119, S47-S53 (2006).
15. Masson, S. et al.; GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur. J. Heart Fail. 12, 338-347 (2010).
16. Chatterjee, K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am. J. Cardiol. 95, 8B-13B (2005). (Pubitemid 40545927)
17. Papassotiriou, J., Morgenthaler, N.G., Struck, J., Alonso, C. & Bergmann, A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin. Chem. 52, 1144-1151 (2006). (Pubitemid 43794428)
18. Khan, S.Q. et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115, 2103-2110 (2007). (Pubitemid 46659061)
19. Neuhold, S. et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at diferent stages of the disease. J. Am. Coll. Cardiol. 52, 266-272 (2008). (Pubitemid 351957847)
20. Sabatine, M.S. et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 125, 233-240 (2012).
21. Kalra, P.R., Moon, J.C. & Coats, A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 85, 195-197 (2002). (Pubitemid 35245980)
22. Goldsmith, S.R. & Gheorghiade, M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 46, 1785-1791 (2005). (Pubitemid 41579797)
23. Gheorghiade, M. et al.; Efcacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical efects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297, 1332-1343 (2007). (Pubitemid 46513234)
24. Udelson, J.E. et al. Acute hemodynamic efects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104, 2417-2423 (2001). (Pubitemid 33108374)
25. Cesari, M. et al. Infammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317-2322 (2003). (Pubitemid 37413536)
26. Kempf, T. et al. Prognostic utility of growth diferentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054-1060 (2007). (Pubitemid 47348231)
27. Mann, D.L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004). (Pubitemid 38451714)
28. Chung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A. & Willerson, J.T.; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infiximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003). (Pubitemid 36793081)
29. Bozkurt, B. et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103, 1044-1047 (2001). (Pubitemid 32200174)
30. Deswal, A. et al. Safety and efcacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99, 3224-3226 (1999). (Pubitemid 29293430)
31. Foley, P. W. et al. Growth diferentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur. Heart J. 30, 2749-2757 (2009).
32. Anand, I.S. et al. Serial measurement of growth-diferentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122, 1387-1395 (2010).
33. Heringlake, M. et al. Growth diferentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratifcation in cardiac surgery patients. J. Am. Coll. Cardiol. 61, 672-681 (2013).
34. Suzuki, T., Yamazaki, T. & Yazaki, Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res. 51, 489-494 (2001). (Pubitemid 32718597)
35. Maisel, A.S. & Daniels, L.B. Breathing not properly 10 years later: what we have learned and what we still need to learn. J. Am. Coll. Cardiol. 60, 277-282 (2012).
36. Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N. & Lee, R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007). (Pubitemid 46871338)
37. Ky, B. et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4, 180-187 (2011).
38. Jougasaki, M. & Burnett, J.C. Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 66, 855-872 (2000). (Pubitemid 30084473)
39. Adlbrecht, C. et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur. J. Heart Fail. 11, 361-366 (2009).
40. Sawyer, D.B. Anthracyclines and heart failure. N. Engl. J. Med. 368, 1154-1156 (2013).
41. Ky, B. et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120, 310-317 (2009).
42. Ahmad, T. & Felker, G.M. Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? J. Am. Coll. Cardiol. 60, 2313-2315 (2012).
43. Weir, R.A. et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 55, 243-250 (2010).
44. Gao, R. et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efcacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 55, 1907-1914 (2010).
45. Jabbour, A. et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail. 13, 83-92 (2011).
46. Ahmad, T. & Felker, G.M. Galectin-3 in heart failure: more answers or more questions? J. Am. Heart Assoc. 1, e004374 (2012).
47. Sharma, U. et al. Novel anti-infammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am. J. Physiol. Heart Circ. Physiol. 294, H1226-H1232 (2008). (Pubitemid 351468718)
48. Sharma, U.C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128 (2004). (Pubitemid 39492008)
49. Felker, G.M. et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ. Heart Fail. 5, 72-78 (2012).
50. van Kimmenade, R.R. et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
51. Zannad, F., Alla, F., Dousset, B., Perez, A. & Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival beneft of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102, 2700-2706 (2000).
52. Ambardekar, A.V. & Buttrick, P.M. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular efects. Circ. Heart Fail. 4, 224-233 (2011).
53. Gullestad, L. et al.; CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur. Heart J. 33, 2290-2296 (2012).
54. Kociol, R.D., Pang, P.S., Gheorghiade, M., Fonarow, G.C., O'Connor, C.M. & Felker, G.M. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J. Am. Coll. Cardiol. 56, 1071-1078 (2010).
55. Januzzi, J.L. Jr, Filippatos, G., Nieminen, M. & Gheorghiade, M. Troponin elevation in patients with heart failure: on behalf of the third Universal Defnition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur. Heart J. 33, 2265-2271 (2012).
56. Felker, G.M. Biomarkers as surrogate end points in heart failure trials. Heart Fail. Clin. 7, 501-507 (2011).
57. Damman, K. et al. Current and novel renal biomarkers in heart failure. Heart Fail. Rev. 17, 241-250 (2012).
58. Comnick, M. & Ishani, A. Renal biomarkers of kidney injury in cardiorenal syndrome. Curr. Heart Fail. Rep. 8, 99-105 (2011).
59. Lassus, J. & Harjola, V.P. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail. Rev. 17, 251-261 (2012).
60. Bolignano, D., Coppolino, G., Lacquaniti, A. & Buemi, M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confnes of nephrology. Eur. J. Clin. Invest. 40, 273-276 (2010).
61. Bonventre, J.V. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol. Dial. Transplant. 24, 3265-3268 (2009).
62. Manzano-Fernández, S. et al. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am. J. Cardiol. 103, 1753-1759 (2009).
63. Damman, K. et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J. Am. Coll. Cardiol. 57, 2233-2241 (2011).
64. Mishra, J. et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 15, 3073-3082 (2004). (Pubitemid 39578839)
65. Allen, L.A. Use of multiple biomarkers in heart failure. Curr. Cardiol. Rep. 12, 230-236 (2010).
66. Cook, N.R. & Ridker, P.M. Advances in measuring the efect of individual predictors of cardiovascular risk: the role of reclassifcation measures. Ann. Intern. Med. 150, 795-802 (2009).
67. Hlatky, M.A. et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientifc statement from the American Heart Association. Circulation 119, 2408-2416 (2009).
68. Freidlin, B., McShane, L.M. & Korn, E.L. Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst. 102, 152-160 (2010).
69. Desai, A.S. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation 127, 509-16; discussion 516 (2013).
70. Felker, G.M., Hasselblad, V., Hernandez, A.F. & O'Connor, C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am. Heart J. 158, 422-430 (2009).
71. Januzzi, J.L. Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch. Cardiovasc. Dis. 105, 40-50 (2012).
72. Masson, S. et al.; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J. Am. Coll. Cardiol. 52, 997-1003 (2008).
73. Januzzi, J.L. & Troughton, R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 127, 500-7; discussion 508 (2013).
74. Ky, B. et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ. Heart Fail. 5, 183-190 (2012).
75. Pham, M.X. et al.; IMAGE Study Group. Gene-expression profling for rejection surveillance after cardiac transplantation. N. Engl. J. Med. 362, 1890-1900 (2010).